RiMO-301, radiation, and pembrolizumab before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests injecting a new drug (RiMO-301) into the tumor, then giving a short course of radiation with the immunotherapy pembrolizumab before surgery for head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that can be surgically removed.
- The tumor chosen for treatment can be measured on scans and is accessible for injection and radiation.
- You have not had radiation to that specific tumor area in the last 6 months, or if you did, it was without complications.
- You are healthy enough to have a performance status of 0-2 (able to do daily activities with little or no help).
- Your blood counts, liver and kidney function are within certain safe limits.
- You are not pregnant or breastfeeding, and if female with childbearing potential, you agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with low-dose radiation and chemotherapy for advanced head and neck cancer. It aims to see if this approach can help patients who have not had prior treatment for their cancer.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial studies RiMO-301 injection combined with palliative radiation and a PD-1 immune therapy (pembrolizumab or nivolumab) for head and neck cancer that cannot be fully removed. It aims to see whether this approach can shrink tumors and improve outcomes safely.
This trial tests a combination of immunotherapy and radiation focused on the neck area for certain types of head and neck cancer. The goal is to help the body's immune system better recognize and attack cancer cells.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.